| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $42.1M | — | +1.6% |
| SG&A Expense | $11.6M | — | -14.5% |
| Operating Income | -$53.7M | — | +2.4% |
| Net Income | -$49.7M | — | -2.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $75.1M | -15.0% | -2.1% |
| Short-term Investments | $276.8M | -4.4% | +21.8% |
| Current Assets | $361.4M | -6.6% | +13.7% |
| Total Assets | $403.0M | -10.1% | -30.5% |
| Current Liabilities | $35.2M | -6.9% | +28.5% |
| Total Liabilities | $36.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$46.0M | — | -6.7% |
| Investing Cash Flow | $32.4M | — | -11.9% |
| Financing Cash Flow | $380K | — | — |
| +32.2% |
| Stockholders' Equity | $366.2M | -10.4% | -33.6% |